State Board of Administration of Florida Retirement System lowered its stake in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 0.6% during the 1st quarter, according to its most recent filing with the SEC. The firm owned 2,219,254 shares of the biopharmaceutical company’s stock after selling 13,516 shares during the period. State Board of Administration of Florida Retirement System owned approximately 0.14% of Bristol-Myers Squibb worth $105,881,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently bought and sold shares of BMY. Vanguard Group Inc grew its holdings in Bristol-Myers Squibb by 1.0% during the 3rd quarter. Vanguard Group Inc now owns 128,376,159 shares of the biopharmaceutical company’s stock valued at $7,969,593,000 after buying an additional 1,229,553 shares in the last quarter. BlackRock Inc. grew its holdings in Bristol-Myers Squibb by 0.9% during the 4th quarter. BlackRock Inc. now owns 115,573,078 shares of the biopharmaceutical company’s stock valued at $6,007,489,000 after buying an additional 999,193 shares in the last quarter. Northern Trust Corp grew its holdings in Bristol-Myers Squibb by 4.4% during the 4th quarter. Northern Trust Corp now owns 22,576,884 shares of the biopharmaceutical company’s stock valued at $1,173,547,000 after buying an additional 954,877 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in Bristol-Myers Squibb by 1.1% during the 4th quarter. Bank of New York Mellon Corp now owns 17,303,884 shares of the biopharmaceutical company’s stock valued at $899,456,000 after buying an additional 180,711 shares in the last quarter. Finally, Norges Bank purchased a new stake in Bristol-Myers Squibb during the 4th quarter valued at approximately $797,038,000. Institutional investors and hedge funds own 77.53% of the company’s stock.
In other news, Director Theodore R. Samuels II purchased 5,000 shares of the business’s stock in a transaction dated Thursday, May 16th. The shares were purchased at an average price of $47.29 per share, for a total transaction of $236,450.00. Following the completion of the purchase, the director now owns 27,000 shares in the company, valued at approximately $1,276,830. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, insider Karen Murphy Santiago sold 3,065 shares of the firm’s stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $47.56, for a total value of $145,771.40. Following the transaction, the insider now owns 3,066 shares in the company, valued at approximately $145,818.96. The disclosure for this sale can be found here. 0.13% of the stock is currently owned by company insiders.
Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported $1.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.09 by $0.01. Bristol-Myers Squibb had a return on equity of 48.72% and a net margin of 22.23%. The company had revenue of $5.92 billion during the quarter, compared to the consensus estimate of $5.72 billion. During the same period last year, the company earned $0.94 earnings per share. Bristol-Myers Squibb’s revenue was up 14.0% on a year-over-year basis. On average, equities research analysts expect that Bristol-Myers Squibb Co will post 4.2 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, August 1st. Stockholders of record on Friday, July 5th will be given a dividend of $0.41 per share. The ex-dividend date of this dividend is Wednesday, July 3rd. This represents a $1.64 annualized dividend and a dividend yield of 3.55%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 41.21%.
A number of equities research analysts have issued reports on BMY shares. BMO Capital Markets increased their price objective on shares of Bristol-Myers Squibb from $62.00 to $63.00 and gave the company an “outperform” rating in a report on Wednesday, April 17th. Zacks Investment Research downgraded Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a research report on Thursday, March 28th. Goldman Sachs Group initiated coverage on Bristol-Myers Squibb in a research report on Tuesday, May 28th. They set a “buy” rating and a $54.00 target price for the company. ValuEngine downgraded Bristol-Myers Squibb from a “sell” rating to a “strong sell” rating in a research report on Thursday, April 4th. Finally, Argus downgraded Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $46.36 target price for the company. in a research report on Monday, May 20th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating and nine have issued a buy rating to the company’s stock. Bristol-Myers Squibb currently has a consensus rating of “Hold” and an average price target of $56.34.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
Read More: What is a CD ladder?
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.